Powered by

ACC: New owner Novartis presents pooled inclisiran data cutting LDL cholesterol by half

Mar 28, 2020 - FierceBiotech

A new, late-phase analysis of the cholesterol-lowering inclisiran—a PCSK9 drug picked up by Novartis through its $9.7 billion acquisition of The Medicines Company—showed that it was able to cut LDL levels by 51% after nearly a year-and-a-half of treatment.

A new analysis of the cholesterol-lowering inclisiran could add some juice to the PCSK9 drug—which Novartis picked up in its $9.7 billion purchase of The Medicines Company last year—showing it was able to cut LDL levels by 51% af...